Reports Q1 revenue $77.06M, consensus $80.25M. “The strength of our company’s first-quarter performance reflects our ongoing commitment to driving top-line revenues, controlling operating expenses, advancing our pipeline, and improving our capital structure,” said Denny Lanfear, Coherus’ Chairman and Chief Executive Officer. “The progress we reported today aligns with these objectives, consistent with our overarching mission to become a sustainable and growing oncology company improving outcomes for cancer patients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHRS:
- Coherus Biosciences Embarks on Strategic Financial Restructuring
- Coherus Biosciences announces clinical collaboration with CRI
- Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics’ ENB-003 for the Treatment of Ovarian Cancer
- CHRS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Coherus to Report First Quarter 2024 Financial Results on May 9, 2024